…morning. icon-camera https://www.isass.org/event_galleries/2012_03_isass12_wed_morning/ zoomIn flat_box 1/3 https://www.isass.org/event_galleries/2012_03_isass12_wed_afternoon/slides/DSC_0020.JPG ISASS12 – Wednesday PM Wednesday, March 21, 2012 afternoon. icon-camera https://www.isass.org/event_galleries/2012_03_isass12_wed_afternoon/ zoomIn flat_box 1/3…
Read More…Near East (S.P.I.N.E.) Near East S.P.I.N.E. zoomIn partner-image image 1/4 https://www.isass.org/wp-content/uploads/2016/02/spinefoundation.png center http://www.spinefoundation.info/ 1 Büttner-Janz Spinefoundation Büttner-Janz Spinefoundation zoomIn partner-image image 1/4 https://www.isass.org/wp-content/uploads/2016/02/spine-care-alliance.jpg center http://www.spinecarealliance.org/…
Read More…Maislin DG, Keenan BT, Maislin G. One-Year NDI and VAS Outcomes from the Single-Level PEEK-on-Ceramic SimplifyTM Disc FDA IDE Trial. J Spine Neurosurg. 2019;2019. doi:10.4172/2325-9701.1000320 Leven D, Meaike J,…
Read More…doi:10.1097/BSD.0000000000000025 Geisler FH, Maislin DG, Keenan BT, Maislin G. One-Year NDI and VAS Outcomes from the Single-Level PEEK-on-Ceramic SimplifyTM Disc FDA IDE Trial. J Spine Neurosurg. 2019;2019. doi:10.4172/2325-9701.1000320 Leven…
Read More…to discuss the anticompetitive effects that the proposed mergers would likely have on the nation’s physicians. Access more information at the following link: http://www.ama-assn.org/ama/pub/news/news/2015/2015-09-08-analysis-anthem-cigna-aetna-humana-mergers.page Antitrust In Medicine Morgan Lorio,…
Read More…Garο¬n SR, et al. Two-year fusion rate equivalency between Grafton DBM gel and autograft in posterolateral spine fusion: a prospective con- trolled trial employing a side-by-side comparison in the s…
Read More…icon_position=”right” link=”https://www.isass.org/education/conferences/isass17-conference-schedule/” color=”#3795d4″ font_color=”#FFFFFF” large=”1″] [button title=”CME Information” icon=”icon-right-open” icon_position=”right”…
Read More…icon=”icon-right-open” icon_position=”right” link=”https://www.eventscribe.net/2021/ISASS/index.asp?” color=”#3795d4″ font_color=”#FFFFFF” large=”1″] left no-repeat;center top;; auto 10px zoomIn Vertebral Columns Promo left no-repeat;center top;;…
Read MoreOn Nov. 1, as part of the OPPS/ASC Final Rule, CMS also finalized policies on price transparency. These policies follow directives in President Trump’s Executive Order, “Improving Price and…
Read More…1 studies demonstrating decreased adjacent segment degeneration, minimal component wear issues, and lower revision rates than fusion. Rationale A common definition of an experimental technique is one that is…
Read MoreOn June 25, the White House announced an initiative to encourage greater transparency in drug pricing. President Trump signed an Executive Order on June 25, entitled “Improving Price and…
Read More…program requires surgeons in Florida, Kentucky, Louisiana, Nevada, New Jersey, North Dakota, Ohio, Oregon, and Rhode Island to report on claims data on post-operative visits furnished during the global…
Read More